US/UK/Canada

Share

Pick a time period -
Tags ( Active)

OPERATING INCOME SEK 24.2 million (22.9) JAN-DEC 2015

YEAR-END REPORT 2015For the October-December period · Net sales for the period were SEK 34.7 million (30.7). · Operating income (EBIT) for the period was SEK 9.1 million (9.5). · Operating margin for the period was 26 percent (31). · Earnings after tax for the period amounted to SEK 5.6 million (7.2). · Earnings per share, basic and diluted, for the period were SEK 0.05 (0.05). For the January-December period · Net sales for the period were SEK 134.5 million (125.2). · Operating income (EBIT) for the period was SEK 24.2 million (22.9). · Operating margin for

OPERATING INCOME +38% JAN-MAR 2015

OPERATING INCOME +38% JAN-MAR 2015 INTERIM REPORT JANUARY-MARCH 2015. For the January-March period ·Net sales for the period were SEK 33.7 million (30.6). ·Operating income (EBIT) for the period was SEK 5.8 million (4.2). ·Operating margin for the period was 17 percent (14). ·Earnings after tax for the period were SEK 5.5 million (1.3). ·Earnings per share for the period, basic and diluted, were SEK 0.05 (0.01). Significant events in the first quarterAllenex acquired all minority holdings in the group from SSP Primers AB for SEK 20 million.

Allenex acquires all remaining minority interests in the group

Allenex AB (publ) (”Allenex”) has signed an agreement to acquire all SSP Primers AB’s ("SSP Primers") shares in Olerup SSP AB, AbSorber AB, Olerup International AB and Olerup Inc. The acquisition will make Allenex the sole owner of all companies in the Allenex group. At the same time, Allenex acquires SSP Primers’ claim on Olerup Inc. of about 4 million SEK. These acquisitions are financed by loans made available by the company's main bank and by payments from Allenex to SSP Primers over a period of three years.Pursuant to the agreement Allenex acquires 9% of Olerup SSP AB, 1.9% of AbSorber

OPERATING INCOME 22,9 MILLION (9,6) JAN – DEC 2014

YEAR END REPORT JAN – DEC 2014For the period October- December ·Net sales for the period amounted to SEK 30.7 million (29.4). ·Operating income (EBIT) for the period was SEK 9.5 million (2.2). ·Operating margin for the period was 31 percent (8). ·Earnings after tax for the period rose to SEK 7.2 million (0.1). ·Earnings per share for the period, basic and diluted, was SEK 0.05 (0.02). For the period January-December ·Net sales for the year amounted to SEK 125.2 million (111.8). ·Operating income (EBIT) for the year was SEK 22.9 million (9.

NET SALES +15% JANUARY - SEPTEMBER 2014

INTERIM REPORT JANUARY - SEPTEMBER 2014.For the July –September period          ·Net sales for the period rose to SEK 32.4 million (28.4). ·Operating income (EBIT) for the period was SEK 7.3 million (2.8). ·Operating margin for the period rose to 22 percent (9). ·Earnings after tax for the period was SEK 6.4 million (-0.3). ·Earnings per share for the period, basic and diluted, were SEK 0.05 (0.00). For the January – September period ·Net sales for the period rose to SEK 94.5 million (82.4). ·Operating income (EBIT) for the period was SEK

Sales +15% jan-jun 2014

Sales +15% jan-jun 2014 INTERIM REPORT JANUARY - JUNE 2014 For the April-June period ·Net sales for the period rose to SEK 31.5 million (27.2). ·Operating income (EBIT) for the period was SEK 2.0 million (2.6). ·Operating margin for the period was 6 percent (9). ·Earnings after tax for the period was SEK 0.4 million (2.5). ·Earnings per share for the period, basic and diluted, was SEK 0.00 (0.02). For the January-June period ·Net sales for the period rose to SEK 62.1 million (54.0). ·Operating profit (EBIT) for the period was SEK 6.2

LinkMed acquire major sales channel

LinkMed acquires NorDiag´s 50 percent stake in Olerup International AB, which is the holding company for Olerup GmbH. LinkMed will thereby control 75 percent of the company. Both sales and earnings are consolidated into the Group as of June 1, 2011. Net sales are expected to increase on an annual basis by approximately SEK 28 million and the profit on EBIT level of SEK 8-10 million.LinkMed increases its ownership in Olerup International AB to 75 percent by acquiring NorDiag 50 percent stake in Olerup International AB which is the holding company of Olerup GmbH. The remaining 25 percent of

Olerup SSP broadens its portfolio with HLA Sequencing Based Typing products from Australian company Conexio

LinkMed transplantation company Olerup SSP has signed an exclusive five-year global marketing, sales and distribution agreement with the Australian company Conexio for Conexio’s SBT Resolver™- HLA Sequencing Based Typing product line and sequence analysis software. Olerup SSP will now be able to broaden its product offer towards the HLA community.Conexio’s SBT Resolver™ products are locus specific PCR based HLA sequencing based typing (SBT) reagents. The agreement includes SBT kits and a version of Assign™ sequence analysis software. The SBT product line will be a strong complement to the

Olerup SSP’s entire HLA typing range now ready for sales in the U.S.

Olerup SSP, a wholly owned subsidiary of LinkMed, has had its Taq-polymerase-free HLA typing kit registered and cleared by the FDA. This means that Olerup SSP’s entire product range for HLA typing, with or without Taq polymerase, can now be marketed and sold to a greater number of healthcare centers in North America. The U.S. is the single largest market for HLA typing and represents over 40 percent of the global tissue typing market. Olerup SSP’s HLA typing kit with Taq polymerase has been approved by the FDA for sale in the United States since March 2009.“Olerup SSP’s products are

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media